CNS Pharmaceuticals, Inc.
CNSP
$5.52
-$0.60-9.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -85.05% | -35.52% | 44.78% | -35.41% | 43.34% |
| Total Depreciation and Amortization | 42.86% | -36.36% | 0.00% | 10.00% | 25.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 373.51% | -15.14% | -65.06% | -51.96% | -85.04% |
| Change in Net Operating Assets | 174.62% | 134.27% | -400.35% | 141.06% | -17.57% |
| Cash from Operations | -40.36% | 59.31% | -64.82% | 40.74% | 19.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 66.15% | -2.36% | -2.30% | -178.53% | 66.12% |
| Issuance of Common Stock | 62,612.50% | -99.98% | -50.02% | 80.50% | -59.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,173.33% | -- | -100.00% | 8,920.00% | 75.00% |
| Cash from Financing | 544.21% | -102.07% | -54.97% | 98.02% | -59.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.53% | -146.90% | -113.93% | 1,387.12% | -109.33% |